Vir Biotechnology, Inc. Share Price & Technical Analysis
VIR · $9.19 (+1.77%)
Healthcare / Biotechnology
$9.19
+1.77%
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those tar…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-10% return in May, 3% avg return in past 3 year May month.
51% return in 2026, -21% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 23% | 25% | 1% | 12% | -10% | – | – | – | – | – | – | – | 51% |
| 25 | 41% | -18% | -21% | -5% | -20% | 2% | 2% | -2% | 16% | 5% | 8% | -3% | 7% |
| 24 | -6% | 19% | -11% | -16% | 23% | -16% | 16% | -17% | -7% | 1% | 13% | -8% | -9% |
| 23 | 16% | -22% | 3% | 9% | 7% | -5% | -42% | -10% | -27% | -16% | 20% | 7% | -60% |
| 22 | -18% | -27% | 3% | -21% | 28% | 1% | 10% | -14% | -18% | 13% | 26% | -8% | -26% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.55B
P/E ratio
—
52W high
$11.66
52W low
$4.16
Volume
12,09,273
Beta
1.70
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Vir Biotechnology, Inc. share price today?
- Vir Biotechnology, Inc. (VIR) last traded around $9.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VIR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VIR. Download the app for real-time alerts.
- How can I analyze Vir Biotechnology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.